Market Research Report
Global Markets for Drug Repurposing
|Published by||BCC Research||Product code||347802|
|Published||Content info||103 Pages
Delivery time: 1-2 business days
|Global Markets for Drug Repurposing|
|Published: January 1, 2016||Content info: 103 Pages||
The global market for drug repurposing will grow from nearly $24.4 billion in 2015 to nearly $31.3 billion by 2020, with a compound annual growth rate (CAGR) of 5.1% for the period of 2015-2020.
This report provides a global overview of drug repurposing, also known as repositioning or reprofiling, including the techniques and applications in various therapies. The report deals with the global market for repurposed drugs in three main areas: market by application of repurposed drugs, by usage of repurposed drugs and by application site (i.e., whether they are used orally or intravenously). The application area is divided into types of disorders (i.e., repurposed drugs in central nervous disorders, cardiovascular disorders, oncology, metabolic, autoimmune and other disorders). Market by usage is analyzed on the basis that repurposed drugs are used alone in single therapy or used in combination with other drugs.
Excluded from this report are drugs that are not yet approved as repurposed drugs. BCC Research analyzes the market and its applications, regulatory environment, technologies involved, market projections and market shares. The market is mainly divided into theU.S.and the rest of the world (ROW).
Also included in the report are relevant patent analysis and comprehensive profiles of the leading companies in the drug repurposing market. The key players are Novartis AG, Abbott Healthcare, Pfizer Inc., Johnson & Johnson and Hoffmann-La Roche. Other significant players are the generic drug manufacturers such as Sandoz, Mylan Inc., and Teva Pharmaceuticals. The chapter on company profiles also includes even core drug repurposing companies such as SOM Biotech, Biovista Inc. and Sosei Group Ltd.
The study has been carried out by a team of professionals in the biotechnology industry. The project manager for this project is Shalini S. Dewan, who holds a master's degree in pharmaceutical chemistry and has over 14 years of industry experience. Shalini was awarded a Gold Medal by the Prime Minister of India for her work and has worked with top companies inIndiaand in theU.S.